Summary:
In this presentation, Dr. Rebecca Riggins presents new findings on how anti-HER2 therapy reshapes estrogen receptor (ER) activity in triple-positive breast cancer. Using high-resolution chromatin mapping, her team reveals that trastuzumab and pertuzumab treatment drives nuclear HER2 localization, expands ER chromatin binding, and activates WNT and RAGE pathway genes-mechanisms linked to poor clinical outcomes. These insights highlight the complexity of receptor crosstalk and the need for integrated therapeutic strategies.
Topics to be covered:
- Nuclear HER2 signaling and its role in resistance to anti-HER2 therapy in triple-positive breast cancer
- Estrogen receptor reprogramming and chromatin remodeling following trastuzumab/pertuzumab treatment
- Identification of WNT and RAGE pathway gene activation linked to poor outcomes in HER2-positive breast cancer
Speakers:
Rebecca B. Riggins, PhDAssociate Professor of Oncology,
Georgetown Lombardi Comprehensive Cancer Center
Browse Our Webinar Library